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Increased cytotoxic drug delivery to liver metastases may be
achieved by regional administration, as these tumours are thought
to derive their blood supply predominantly from the hepatic artery
(Ackerman et al, 1974). The response rate of colo-rectal liver
metastases to hepatic arterial chemotherapy is approximately 50%
(Rougier, 1998), and one of the factors limiting treatment success is
thought to be low levels of drug uptake resulting from poor vascu-
larity and blood flow in a proportion of these tumours (Daly et al,
1985). Enhancement of tumour blood flow may be expected to
increase drug uptake and hence lead to improved tumour response.
Intra-arterial administration of vasoconstrictor agents may selec-
tively increase liver vascular resistance and shunt blood into non-
responsive tumour vessels, thereby increasing the tumour : normal
blood flow ratio (Hafström et al, 1980). 
Angiotensin II is a powerful vasoconstrictor which has been
shown to alter the distribution of blood flow in favour of intra-
hepatic tumour perfusion during short (3–4 min) intra-arterial
infusions of the compound (Sasaki et al, 1985). Enhanced tumour
targeting of radiolabelled microspheres as a consequence of modi-
fied hepatic blood flow distribution has also been demonstrated
following 100s of intra-arterial infusions (Goldberg et al, 1991).
Whether or not prolonged intra-arterial infusion of Angiotensin II
can lead to sustained enhancement of tumour : normal blood flow
ratio in humans is presently not known, and is an important factor
in determining the practical value of this method of vascular
manipulation for use with regional chemotherapy. 
Copper(II) pyruvaldehyde bis(N-4-methylthiosemicarbazone)
(Cu-PTSM) is a small lipophilic molecule currently under evaluation
as a ‘tissue trapping’ blood flow tracer for use with Positron
Emission Tomography (PET) (Wallhaus et al, 1998), and which has
been shown to exhibit efficient single-pass extraction from the circu-
lation following intra-arterial injection at up to moderate levels of
blood flow (Mathias et al, 1990). Prolonged tissue retention, and no
evidence of tracer accumulation in the liver (Wallhaus et al, 1998),
suggest the potential use of Cu-PTSM and PET for quantitative
assessment of intrahepatic blood flow distribution. Furthermore, Cu-
PTSM may be labelled using the short half-life positron emitter 62Cu
(t1/2 = 9.7 min), thereby enabling short intervals to be selected
between repeat measurements in the same patient. 
In this study, 62Cu-PTSM and PET have been used to assess the
relative distribution of hepatic arterial flow to tumour and liver
parenchyma, where the aim was to examine blood flow changes
during and following a 45 min hepatic arterial Angiotensin II infu-
sion in patients with colo-rectal liver metastases. 
MATERIALS AND METHODS 
Patient selection 
The study included patients with unresectable colo-rectal liver
metastases, and no evidence of extrahepatic disease as determined
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by abdominal CT scan and chest X-ray, who had undergone
hepatic arterial cannulation and insertion of an Infusaid model 400
pump (Norwood, Massachussets, USA) for regional floxuridine
infusion chemotherapy (0.2 mg per kg body weight per 24 h over
14 days) (Allen-Mersh et al, 1994). At the time of study patients
had received between 1 and 7 cycles of treatment. Exclusion
criteria were: age > 70 years; Karnofsky score < 80; jaundice, or a
history of hypertension, myocardial or cerebrovascular disease.
Blood pressure was measured prior to the study, and patients were
excluded if the systolic blood pressure was > 160 mmHg or the
diastolic pressure was > 85 mmHg on two successive recordings
30 min apart. Ten patients were included in the study. 
Approval for the study was granted by the Royal Marsden NHS
Trust Ethics Committee, and the Committee for Clinical Research.
Written informed consent was obtained from all patients. 
Tracer preparation and PET imaging 
Radionuclide preparation was carried out using an in-house
62Zn/62Cu generator (Zweit et al, 1992), and full details of the
preparation of 62Cu-PTSM from H2-PTSM ligand have been
described elsewhere (Flower et al, 2001). Radiochemical purity of
tracer was assessed by instant thin layer chromatography prior to
administration and was   91% in all cases. 
PET imaging was carried out using a multi-wire proportional
chamber positron camera (MUP-PET) (Marsden et al, 1989). The
data acquisition protocol was optimized for PET imaging with
62Cu (Flower et al, 1996, 2001), and images were reconstructed
into a 64 × 64× 64 matrix of 6 mm cubic voxels, The ANALYZE
software package (Robb and Barillot, 1998) was used for image
display and subsequent ROI analysis. 
Angiotensin II 
Angiotensin II was obtained as a gift from Novartis (Frimley, UK).
For each preparation 2.5 mg Angiotensin II was diluted to a
concentration of 5 µ g/ml in 500 ml saline. This was administered
using an IMED infusion pump (Alaris Medical, Basingstoke, UK),
at a continuous rate of 1 ml/min over 45 min, to deliver an
Angiotensin II dose of 5 µ g/min. 
PET imaging procedure 
Patients were positioned on the PET scanning couch such that the
liver was centred in the 15 cm axial field of view. Then 80–100
MBq 62CuPTSM was injected into the sideport of the implanted
infusion pump to pass into the liver via the hepatic artery, and a
baseline PET scan obtained. Immediately following the comple-
tion of the PET scan (approx. 40 min), a continuous Angiotensin II
infusion was commenced via the pump sideport. After 10 min of
Angiotensin II infusion, a second injection of 62CuPTSM was
given followed by a further PET scan. The Angiotensin II infusion
was stopped after 45 min total duration and followed immediately
by a final injection of 62CuPTSM and PET scan. Systolic (SP) and
diastolic (DP) blood pressure and pulse rate were monitored
throughout the procedure at 2 min intervals using a Dynamap
machine (Johnson & Johnson, Berkshire, UK), and mean arterial
blood pressure (MAP) was derived as (DP+(SP-DP)/3). In order to
assess reproducibility of the PET measurements, in one patient an
infusion of physiological saline was substituted for Angiotensin II. 
Data analysis 
Contrast enhanced X-ray CT scans taken prior to the PET study
were used to confirm metastatic sites within the liver, and as a
guide to defining tumour regions of interest (ROIs) on corre-
sponding slices of the PET images. ROIs were drawn around areas
of normal liver and within tumour on the PET images. Depending
on the shape of the tumour, circular or irregular ROIs positioned
well within the tumour, to avoid partial volume effects, were used,
and care was taken to avoid any evident necrotic regions. In
normal liver large, irregular ROIs, to allow for liver uptake hetero-
geneity, avoiding both the liver and tumour boundaries, were
drawn in the same slices used to define the tumour ROI. The sizes
of the PET ROIs relative to the tumour and liver volumes as
measured on CT are listed in Table 1. Background subtraction was
applied to correct for scattered photons and random events and
data were summarized as the ratio of tumour : normal liver ROI
values, which was interpreted as an index of intrahepatic blood
flow distribution. The same ROIs were applied to each of the three
sets of PET images for each patient, thereby minimizing uncertain-
ties arising from region definition. The statistical significance of
changes in tumour : normal blood flow ratio, mean blood pressure
and pulse rate during the Angiotensin II infusion was assessed by
paired Wilcoxon test. 
RESULTS 
Nine patients (7 males), mean age 63 years completed the PET and
Angiotensin II study; one further patient was studied by PET with
no Angiotensin II in order to assess the reproducibility of the
blood flow measurements. No adverse side-effects due to adminis-
tration of either 62CuPTSM or Angiotensin II were observed. 
Reproducibility 
Three consecutive 62Cu-PTSM PET measurements in the same
patient with no Angiotensin II intervention resulted in mean
tumour: liver ratios of 4.0 ± 0.2 (± 1 S.D.) and 2.5 ± 0.1 for the two
lesions studied. The time-course of the uptake ratio during the
three repetitive PET measurements has been presented previously
(Flower et al, 2001). Corresponding measurements of MAP and
pulse rate during the PTSM infusion periods gave mean values of
99 ± 1.5 mmHg and 70 ± 2 min–1 respectively. A relative change in
Table 1 Patient data 
Patient CT volume (ml) PET ROI volume (% of CT volume) 
Tumour Liver Tumour Liver 
1 148 1496 34 21 
2 212 1908 23 24 
3 61 3328 13 10 
4 195 1430 5 35 
5 482 1614 20 3 
6*(a) 277 1997 6 35 
6(b) 132 1997 6 35 
7*(a) 417 2570 7 14 
7(b) 1369 2570 7 14 
8 113 3654 36 13 
9 733 1361 14 19 
*Patients with multiple lesions any parameter of > 2 S.D. was deemed to be significant in subse-
quent Angiotensin II studies. 
Response to Angiotensin II 
As expected, infusion of Angiotensin II led to an elevation in MAP
in all patients as shown in Table 2. Although elevated MAP was
sustained for the duration of Angiotensin II infusion, a substantial
return from peak toward baseline levels was seen in all patients
immediately after the infusion was stopped. Overall, there was a
statistically significant (P = 0.008) increase in MAP after 10 min
Angiotensin II infusion (median 114; iqr, 109–115) compared with
baseline values (median 98; iqr, 97–108). No significant changes in
pulse rate were observed throughout the Angiotensin II infusions. 
An example set of 62Cu-PTSM PET images together with a
corresponding X-ray CT scan of the tumour region is shown in
Figure 1. The PET images show non-uniformity of tracer uptake,
i.e. spatial heterogeneity, in both tumour and liver. However the
system resolution was not adequate to base quantification on less
than large-scale averaging. Nevertheless, the ROI analysis was
sufficient to reveal significant changes in tracer distribution
between tumour and liver during the study. 
With one exception, baseline tumour: liver 62Cu-PTSM ratios
(TNRs) were found to be greater than unity and exhibited a wide
range between individual patients as seen in Figure 2. In response
to 10 min Angiotensin II infusion a significant but highly variable
enhancement of TNR was observed in the majority of cases (seven
lesions in seven patients) as seen in Figure 3. The remaining four
lesions in three patients demonstrated either no change or a fall in
TNR, and interestingly two lesions in one patient exhibited
opposite TNR responses. Of the lesions showing increased TNR,
4/7 showed reduced TNR enhancement following the 45 min
Angiotensin II infusion. Nevertheless, TNRs higher than baseline
were sustained in approximately half of the cases studied (six
1642 D Burke et al 
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Figure 1 Contrast enhanced X-ray CT scan (top left) and 62Cu-PTSM PET scans acquired before (top right), during (bottom left) and after (bottom right)
regional infusion of Angiotensin II in a patient (Number 1 in Table 1) with an unresectable liver metastasis. Tumour shows as hypodense areas on the X-ray CT
scan (continuous line) and enhanced tracer uptake is represented by darker areas on the PET scans. The dotted lines indicate the tumour ROI on the PET
images. CT and PET images are not to the same scale Angiotensin II enhancement of liver metastasis blood flow 1643
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lesions in six patients), including three lesions in which no
apparent fall in TNR was observed. Overall there was a statisti-
cally significant (P = 0.008) increase in TNR after 10 min
Angiotensin II infusion (median 2.1; iqr 1.4–4.1) compared with
baseline (median 1.3; iqr, 0.9–2.5), which appeared to be sustained
throughout the 45 min infusion period (median 1.85; iqr, 1.3–3.8;
P = 0.03). The degree of TNR enhancement was not related to the
magnitude of Angiotensin II induced change in MAP (r2 = 0.06),
and neither baseline TNR nor TNR enhancement appeared to be
strongly influenced by the extent of previous chemotherapy
treatment. 
DISCUSSION 
It is accepted that intratumoural blood vessels are immature,
lacking both smooth muscle cells and immunoreactive nerves
(Ashraf et al, 1997). Infusion of Angiotensin II via the hepatic
artery therefore would be expected to constrict normal liver
vessels, so reducing liver blood flow, but leave tumour vessels,
and therefore flow, relatively unaffected. This has previously been
demonstrated with a short Angiotensin II infusion using both
microspheres (Goldberg et al, 1991) and Laser Doppler Flowmetry
(LDF) (Hemingway et al, 1992) to assess blood flow. However,
previous animal studies using LDF (Dworkin et al, 1997), and
clinical studies using planar imaging (Sasaki et al, 1985) have
demonstrated only transient Angiotensin II-induced enhancement
of tumour:normal blood flow ratio, which was not sustained
throughout a prolonged Angiotensin II infusion via the hepatic
artery. This contrasts with the results of our study, where the





















































































Figure 3 AT II induced changes in blood pressure and 62Cu-PTSM uptake
normalized with respect to baseline (pre-administration) levels. The dotted
lines correspond to ±2 standard deviations from mean parameter values
derived using reproducibility data (see text) 























































Figure 2 Changes in blood pressure and tumour normal liver 62Cu-PTSM
uptake ratio associated with regional infusion of Angiotensin II (AT II). Data
from each patient is represented by a different symbol, the dashed lines
corresponding to data from additional tumours in the same patient 
Table 2 Response of blood pressure and 62Cu-PTSM distribution to hepatic arterial Angiotensin II (AT II) infusion 
Patient Previous treatment Blood pressure (mmHg) 62Cu-PTSM uptake (tumour: liver ratio) 
cycles of  Pre Peak during During End   Post  Pre  During Post
chemotherapy AT II AT II** PTSM*** AT II† AT II†† AT II AT II AT II
1 4 97 123 100 121 104 1.28 3.07 2.19 
2 4 94 115 102 102 87 1.89 1.81 1.99 
3 7 97 127 113 123 108 1.22 2.10 1.23 
4 5 110 121 116 117 116 2.56 3.54 3.55 
5 4 98 121 112 118 100 6.21 22.68 9.24 
6*(a) 1 111 138 129 123 120 1.53 1.48 1.04 
6(b) 1.84 1.79 1.59 
7*(a) 1 108 130 121 115 101 1.28 0.63 0.70 
7(b) 2.88 4.25 4.01 
8 6 90 97 93 89 92 4.84 16.02 18.34 
9 1 95 107 106 104 94 0.93 2.10 1.47 
*PTSM uptake recorded separately for multiple lesions. **Single value. ***Mean of 3 values during second PTSM infusion. † Mean of final 3 values during AT II
infusion. †† Mean of 3 values post AT II and during third PTSM infusion. 1644 D Burke et al 
British Journal of Cancer (2001) 85(11), 1640–1645 © 2001 Cancer Research Campaign
some patients. It has been demonstrated that Nitric Oxide (NO) is
the mediator of hepatic parenchymal vasodilatation (Mathie et al,
1991), and NO inhibition has been shown to prolong Vasopressin-
induced vasoconstriction and enhancement of tumour : liver blood
flow ratio in the rat (Dworkin et al, 1995). Further investigation of
NO induced compensatory vasodilation during Angiotensin II
infusion in humans may help to elucidate the mechanisms respon-
sible for the discrepancies seen in the small number of published
studies, and also the wide variation in response seen between
individual patients. However, it should be pointed out that
factors associated with different flow measurement techniques,
Angiotensin II delivery and possible confounding effects of
general anaesthesia in reported LDF studies cannot be ruled out. 
A relative increase in tumoural blood flow would enable higher
doses of regional chemotherapy to be given while avoiding hepa-
totoxicity. Recent results question whether a prolonged increase in
blood flow (i.e. 45 min) is more effective in increasing tumoural
drug uptake than repeated short increases (Netti et al, 1995).
However, small molecules, such as 5-FU, rely upon diffusion to
penetrate tumours. Prolonged increases in tumour blood flow
appear to increase tumour blood volume as a result of reopening
closed capillaries (Netti et al, 1999). Prolonged vasoconstriction
would therefore tend to increase tumour uptake of small mole-
cules. As 5-FU, once inside the cell, undergoes phosphorylation
and is effectively trapped, washout of the drug should not occur. 
The results presented here show that regional administration of
Angiotensin II appears to be safe. As expected, there was a signif-
icant increase in systemic blood pressure in all patients during
hepatic arterial Angiotensin II infusion. However, peak levels of
hypertension were not sustained and a substantial return to base-
line levels occurred in all cases within a few minutes after the infu-
sion was stopped. Although the number of patients included was
small, the variation between individual tumour : normal baseline
flow ratios and the observed pattern of initial response to
Angiotensin II infusion appear to be broadly similar to the previ-
ously reported findings of Goldberg et al (1991). The degree of
Angiotensin II induced TNR enhancement was not found to be
related to the elevation of MAP, contrary to previously reported
findings (Hemingway et al, 1992). This may be attributable to
differences in measurement technique, for example limited
sampling of only the tumour periphery was possible with the
surface probe LDF method used in the previous study. Change in
MAP must therefore be considered an unreliable predictor of
blood flow response during vasoactive manipulation in the liver,
which highlights the need for independent quantitative assessment
of blood flow distribution during these studies. 
An important prerequisite for the objective evaluation of any
vascular manipulation procedure is a quantitative and reliable
method for blood flow assessment. Establishing an appropriate
clinical measurement technique for investigating locoregional
hepatic flow manipulation presents a significant challenge
however, due to the dual blood supply of the liver and the deep
location of many intrahepatic tumours. Of the reported methods
employed to study blood flow or tumour targeting in the liver, each
has specific drawbacks. The excellent temporal resolution of Laser
Doppler Flowmetry (LDF) is well suited to pharmaceutical chal-
lenge tests, as demonstrated by Hemingway et al (1992). However,
the method is unable to discriminate between hepatic arterial and
portal venous flow and the limited sampling of heterogenous tissue
is another disadvantage. Dynamic planar imaging of the freely-
diffusible tracer 81mKr has been used to study Angiotensin II-
induced changes (Sasaki et al, 1985). The extremely short tracer
half-life (t1/2 = 13 s) avoided problems associated with tracer recir-
culation via the portal system, but image quantification is difficult
using planar techniques, and subsequent radiotracer studies have
employed 3D tomographic imaging. 
In a tumour targeting study (Goldberg et al, 1991), SPECT
imaging of 99mTc-labelled albumin microspheres was used.
However, the 6 h half-life of 99mTc and unknown effects of micros-
phere blockade upon regional hemodynamics precludes short-term
repeat measurements using this approach. Alternative methods
using PET offer both improved spatial resolution and tracers with
a short half-life that are compatible with pharmaceutical challenge
tests within a single imaging session. Intra-arterial infusion of the
flow tracer H2
15O, may not represent hepatic blood flow
(Dimitrakopoulou-Strauss et al, 1998). For the present study an
alternative PET method based on the ‘trapping’ tracer Cu-PTSM
was established. The 9.7 min half-life of the 62Cu label was shown
to be compatible with short-interval repeat studies on the same
patient, the minimum interval of approximately 40 min being
determined by the limited sensitivity and count-rate performance
of the PET camera available for this study. 
Non-nutritive blood flow through arteriovenous shunts occurs
more commonly in tumours than in normal tissue (Hennigan et al,
1992) and can affect attempts at blood flow measurement. The Cu-
PTSM tracer is trapped by cells with which it is in contact and so
its distribution represents nutritive flow only. It is this flow which
is clinically relevant as it is likely to deliver chemotherapy to the
tissues. 
In summary, it has been shown that prolonged enhancement of
tumour blood flow relative to liver is feasible using intra-arterial
infusion of Angiotensin II, and that further development of
vascular manipulation to improve drug delivery and tumour
targeting is justified. However, if this approach is to be used effec-
tively then a better understanding is needed of the factors under-
lying individual variations in patient response. PET together with
62Cu-PTSM constitutes a powerful clinical tool for the quantitative
study of vascular manipulation, enabling optimum treatment to be
directed selectively to those patients likely to benefit from the
procedure. 
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